Truist Securities Maintains Buy on IGM Biosciences, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on IGM Biosciences but lowered the price target from $25 to $24.
August 23, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained a Buy rating on IGM Biosciences but lowered the price target from $25 to $24, indicating a slight adjustment in expectations.
The maintenance of a Buy rating suggests continued confidence in the stock, but the slight reduction in the price target indicates a minor adjustment in expectations. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100